Pyrazinoic acid inhibits the bifunctional enzyme (Rv2783) in mycobacterium tuberculosis by competing with tmRNA

Lei He, Peng Cui, Wanliang Shi, Qiong Li, Wenhong Zhang, Min Li, Ying Zhang

Research output: Contribution to journalArticle

Abstract

Pyrazinamide (PZA) is a key drug for tuberculosis treatment. The active form of PZA, pyrazinoic acid (POA), appears to inhibit multiple targets in M. tuberculosis. Recently, the bifunctional enzyme Rv2783 was reported as a new target of POA. However, the mechanism by which POA inhibits Rv2783 is not yet clear. Here, we report how a new A2104C substitution in Rv2783c, identified in PZA-resistant clinical isolates, conferred resistance to PZA in M. tuberculosis. Expression of the mutant allele recapitulated the PZA resistance. All catalytic activities of Rv2783, but not the mutant, were inhibited by POA. Additionally, POA competed with transfer-messenger RNA (tmRNA) for binding to Rv2783, other than the mutant. These results provide new insight into the molecular mechanism of the antitubercular activity of PZA.

Original languageEnglish (US)
Article number230
JournalPathogens
Volume8
Issue number4
DOIs
StatePublished - Dec 2019

Keywords

  • Mycobacterium tuberculosis
  • PNPase
  • Pyrazinamide resistance
  • Rv2783c gene
  • TmRNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Biology
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pyrazinoic acid inhibits the bifunctional enzyme (Rv2783) in mycobacterium tuberculosis by competing with tmRNA'. Together they form a unique fingerprint.

  • Cite this